Source: Υπουργείο Υγείας (CY) Revision Year: 2019 Publisher: Remedica Ltd, Aharnon Street, Limassol Industrial Estate, 3056 Limassol, Cyprus
Pharmacotherapeutic group: Antibacterials for systemic use; Tetracyclines
ATC code: J01AA02
Remycin is primarily bacteriostatic and is believed to exert its antimicrobial effect by the inhibition of protein synthesis. Remycin is active against a wide range of Gram-positive and Gram-negative bacteria and certain other micro-organisms.
Remycin has a high degree of lipid solubility and a low affinity for calcium. It is highly stable in normal human serum. Remycin will not degrade into an epianhydro form.
Tetracyclines are readily absorbed and are bound to plasma proteins in varying degrees. They are concentrated by the liver in the bile and excreted in the urine and faeces at high concentrations and in a biologically active form. Doxycycline is virtually completely absorbed after oral administration. Studies reported to date indicate that the absorption of doxycycline, unlike certain other tetracyclines, is not notably influenced by the ingestion of food or milk.
Following a 200 mg dose, normal adult volunteers averaged peak serum levels of 2,6 micrograms/ml of doxycycline at 2 hours decreasing to 1,45 micrograms/ml at 24 hours.
Studies have shown no significant difference in serum half-life of doxycycline (range 18 to 22 hours) in individuals with normal or severely impaired renal function.
Haemodialysis does not alter the serum half-life of doxycycline.
Not applicable.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
